The FDA has approved insulin lispro-aabc as a treatment for adults with type 1 or type 2 diabetes. Manufactured by Eli Lilly and sold under the name Lyumjev, the mealtime insulin was specifically designed to accelerate the absorption of insulin into a patient’s bloodstream and lower A1C levels.
This approval was based on data from two phase III randomized, treat-to-target studies that examined the drug’s performance compared to insulin lispro, another Lilly-manufactured insulin injection sold as Humalog.
“We are proud to build on our long heritage of developing new insulins with the approval of Lyumjev, an important new treatment option to help control post-meal blood sugar levels,” Leonard Glass, MD, vice president of medical affairs for Lilly, said in a statement. “Keeping blood sugar in the target range following meals can be challenging for people living with diabetes, and the approval of Lyumjev underscores our commitment to meeting their needs.”
“Lilly is committed to ensuring all of our insulins, including Lyumjev, are accessible to people living with diabetes through our wide range of affordability options, such as the Lilly Insulin Value Program,” added Adrienne Brown, vice president of U.S. connected care and insulins for Lilly. “We want people who use Lilly insulin and need help affording their medicine to know that we're here to support them.”
Insulin lispro-aabc was approved in other markets, including Japan and the EU, in March 2020.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.